• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Do New Birth Control Pills Increase Risk for Venous Thromboembolism?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • The traditional ‘cyclic’ regimen for combined oral contraceptives (COCs) is 21 days on and 7 days off  
  • Current low-dose estrogen COC use (≤35 µg ethinyl estradiol) is associated with a 2- to 3-fold higher risk for venous thromboembolism (VTE)  
    • This risk represents a small absolute excess risk which is much less than risk levels seen in pregnancy or postpartum  
  • Li et al. (JAMA Internal Medicine, 2018) sought to determine the risk for venous thromboembolism (VTE) when COCs are used with continuous (365/0 days) or extended (84/7 days) regimens

METHODS: 

  • Retrospective cohort study  
  • US population identified from Sentinel Distributed Database 
    • Administrative medical and prescription drug insurance claims and demographic data 
  • Participants 
    • 18 to 50 years old at time of initiating use of COC  
    • Excluded women with medical condition that could impact risk for VTE (e.g., prior VTE or malignancy)  
  • Exposure was either 
    • Continuous/extended COCs 
    • Traditional cyclic COCs 
  • Initiators defined as  
    • No use of the study COCs that were used to define each cohort during a 6-month lookback period 
  • Medication contained ethinyl estradiol or levonorgestrel of any dose 
  • Follow-up was index date until  
    • Earliest occurrence of VTE hospitalization | Health plan disenrollment | Cessation of initiated COC | Initiation of a product of the other COC regimen in comparison or a nonstudy hormone contraceptive | Death | Pregnancy or live birth delivery | End of study period 
  • Primary outcome: First VTE hospitalization that occurred during the study follow-up 
  • Covariates were assessed for confounding including other drug use or medical conditions using propensity scoring

RESULTS: 

  • 210,691 initiators of noncyclic COCs
    • 11,504 continuous COC users | 522, 316 initiators of cyclic COCs 
  • Mean age 
    • Noncyclic: 30.4 years 
    • Cyclic COCs: 28.8 years 
  • Incident VTE cases 
    • Noncyclic COC users: 228  
    • Cyclic COC users: 297  
  • Compared to cyclic COCs, continuous/extended cyclic users had 
    • Higher baseline cardiovascular and metabolic conditions (7.2% vs 4.7%) 
    • More gynecological conditions (39.7% vs 32.3%) 
    • Slightly higher health services utilization  
  • Adjusting for confounding, there was a higher risk for VTE in the continuous/extended group (progestogen type levonorgestrel) 
    • Hazard ratio 1.32 (95% CI, 1.07-1.64)  
  • Adjusting for confounding, the absolute risk difference and the incidence rate difference between the 2 cohorts was low 
    • Absolute risk difference: 0.27 per 1000 persons 
    • Incidence rate difference: 0.35 cases per 1000 person-years 
      • 1.44 vs 1.09 cases per 1000 person-years 

CONCLUSION: 

  • Continuous/extended COCs lead to slightly elevated VTE risk, compared to cyclic COCs 
  • Authors consider the absolute risk to be small and likely not clinically significant and state 

Accordingly, we do not recommend selective prescribing of COCs based on the cyclic and continuous/extended type. Clinicians should prescribe COCs based on patients’ individual risk factors and preferences. 

Learn More – Primary Sources: 

Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Practical info for your gynecology practice
Hormonal Contraception Benefits – Beyond Pregnancy Prevention
ACOG Practice Advisory: Counseling Patients About Breast Cancer Risk and Hormonal Contraception

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site